Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes

Diabetes Therapy

Volumn 7, Issue 4, 2016, Pages 765-776

  Sosale, Bhavana ^a   Sosale, Aravind ^a   Bhattacharyya, Arpandev ^b  

^a Diacon Hospital   (India)

^b Shivajoyti   (India)

Author keywords

Dapagliflozin; Dosage; HbA1c; Health economics; Insulin cost; SGLT2 inhibitors; Sodium glucose co transporter 2 inhibitors; Type 2 diabetes; Weight reduction

Indexed keywords

EID: 84996563561     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-016-0204-9     Document Type: Article

References (42)

1. International Diabetes Foundation. Prevalence of Diabetes in India. 2015. http://www.idf.org/membership/sea/india. Accessed 30 Jun 2016.
2. Standards of Medical Care in. Diabetes-2014: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:S14–80.
3. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249.
4. Norris SL, Nichols PJ, Caspersen CJ, et al. Task Force on Community Preventive Services. The effectiveness of disease and case management for people with diabetes: a systematic review. Am J Prev Med. 2002;22(4S):15–32.
5. Prospective UK. Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125–36.
6. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27:13–20.
7. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, GonderFrederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10–15.
8. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–62.
9. Kapur A. Economic analysis of diabetes care. Indian J Med Res. 2007;125:473–82.
10. Shobhana R, Rao PR, Lavanya A, Williams R, Vijay V, Ramachandran A. Expenditure on health care incurred by diabetic subjects in a developing country—a study from Southern India. Diabetes Res Clin Pract. 2000;48:37–42.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015;38:140–9.
12. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients With Type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695–702.
13. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Debora E. Williams-Herman DEW, for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987.
14. Gruber W, Lander T, Leese B, Songer T, Williams R, editors. The economics of diabetes and diabetes care—a report of diabetes health economics study group. IDF Publication, Brussels. 1997. http://www.who.int/iris/handle/10665/42011
15. Rayappa PH, Raju KNM, Kapur A, Bjork S, Sylvist C, Kumar KM. The impact of socio-economic factors on diabetes care. Int J Diab Dev Countries. 1999;19:7–16.
16. Erpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC EndocrDisord. 2016;16:39.
17. Seufert J. SGLT2 inhibitors—an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543–54.
18. Yacoub Tamer. Dapagliflozin combination therapy in type 2 diabetes mellitus. Postgrad Med. 2016;128:124–36.
19. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.
20. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care. 2011;34:2015–22.
21. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 SGLT2 inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154–1160.
22. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457–466.
23. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–31.
24. Zinman B, Wanner C, Lachin J, et al. for the EMPA REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
25. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm. 2015. Endocr Pract. 2015;21:438–47.
26. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
27. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.
28. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes ObesMetab 2012;14:539–545.
29. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagli- flozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.
30. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J ClinPract. 2013;67:1267–82.
31. Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016;7(4):555–64.
32. Van Haalen HG1, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34:135-46. doi: 10.1007/s40261-013-0155-0.
33. Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–36.
34. Yesudian CAK, Grepstad M, Visinitin E, et al. The economic burden of diabetes in India: a review of the literature. Glob Health. 2014;10:80.
35. Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality of life (HRQoL): a time trade-off survey. J Med Econ. 2013;16:1357–65.
36. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21:402–8.
37. Neal B, Perkovic V, Zeeuw D, et al. on behalf of the CANVAS trial collaborative group. Efficacy and safety of Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes mellitus. Diabetes Care. 2015;38:403–411.
38. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–23.
39. Wilding J, Woo V, Norman G, et al. Long-Term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–15.
40. Udell Jacob A, et al. Glucose lowering drugs or strategies and cardiovascular outcomes in patients with or at risk of type 2 diabetes: a meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinol. 2015;3(5):356–66.
41. Neal B, Perkovic V, Zeeuw D, on behalf of the CANVAS trial collaborative group, et al. Efficacy and safety of Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjuction with insulin therapy in patients with type 2 diabetes mellitus. Diabetes Care 2015;38:403–11.
42. Geerlings S, Fonseca V, Castro-Diaz D, List J. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373–81.